Organization (Academic)
Université de Sherbrooke
ClinicalTrials.gov lists Université de Sherbrooke as lead sponsor of 296 trials. It has 79 active development programs and 37 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 14 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 20 in 2026 and about 25 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (20 to 100), forecasts made part-way through the year were typically off by about 18 percent and ran about 14 percent low against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Logo Université de Sherbrooke, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers Université de Sherbrooke: 296 lead-sponsored trials and 1 legal-entity registration.
Disease areas (228)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Pain | 42 |
| Diabetes Mellitus | 27 |
| Obesity | 22 |
| Acidosis | 19 |
| Ketosis | 19 |
Showing 5 of 228 disease areas.
Trials by start year as sponsor or collaborator (26)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 14 |
| 2025 | 31 |
| 2024 | 17 |
| 2023 | 17 |
| 2022 | 30 |
| 2021 | 21 |
| 2020 | 23 |
| 2019 | 17 |
| 2018 | 16 |
| 2017 | 24 |
Showing 10 of 26 years.
Prediction, not a registry value: median 36 months or more (the model's horizon) from start to primary completion across 35 trials still running at the 2026-10-09 snapshot; 21 of 35 predicted trials reach the 36-month horizon; registered median of 19 months across 183 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (79)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Dupilumab Prefilled Syringe | Asthma | Phase 3 | 1 |
| Androgen blockade + radiation therapy | Prostatic Neoplasms | Phase 3 | 1 |
| Vitamin C | COVID-19 | Phase 3 | 2 |
| CycloSPORINE Ophthalmic | Dry Eye Syndromes | Phase 3 | 1 |
| CBD Oral Solution | Fragile X Syndrome | Phase 2 | 2 |
Showing 5 of 79 active programs.
Approved assets (37)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| ADALIMUMAB | 2 |
| Levothyroxine supplementation | 1 |
| 0.9% NS + AT | 1 |
| Intrathecal Morphine/Sufentanil | 1 |
| Potassium Bicarbonate | 1 |
Showing 5 of 37 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 52% hit target (n=86) | 29% on time (n=90) |
Journals published in (457)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Anesthesia and analgesia | 13 |
| The Journal of trauma | 13 |
| Lancet (London, England) | 12 |
| BMJ open | 9 |
| Medicine and science in sports and exercise | 9 |
Showing 5 of 457 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 74 | 0 | 2020-06-23 |
Organization relationships (45)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Centre de recherche du Centre hospitalier universitaire de Sherbrooke | Co sponsors trial with | 7 |
| Canadian Institutes of Health Research | Co sponsors trial with | 5 |
| University Health Network, Toronto | Co sponsors trial with | 3 |
| Fraxa Research Foundation | Co sponsors trial with | 2 |
| Université de Montréal | Co sponsors trial with | 2 |
Showing 5 of 45 relationships.
Latest dated events (420)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-09-14 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-09-14 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-09 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-08 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-08-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 420 events.
Biomarker capability evidence (195)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| AKR1C1 | Trial sponsor | Named in trial inclusion criteria |
| ASL | Trial sponsor | Named in trial inclusion criteria |
| BCHE | Trial sponsor | Named in trial inclusion criteria |
| BCHE | Trial collaborator | Named in trial inclusion criteria |
| CCNG1 | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 195 evidence rows.
Biomarkers this organization publishes on (463)
Shown in this order: most publications first.
Showing 5 of 463 biomarkers.
On Scientist.com
Université de Sherbrooke is listed as a research supplier in the Scientist.com network.
La pharmacologie moléculaire et structurale s’applique à la compréhension des processus biologiques impliqués dans les pathologies. Cette compréhension se situe tant niveau mécanistique qu’au niveau de l’élucidation de la structure tridimensionnelle des macromolécules et des complexes macromoléculaires en jeu. Une fois cette compréhension acquise, un processus de développement « rationnel » de molécules pouvant moduler ces processus peut être enclenché et éventuellement mener à la découverte de candidats potentiels au développement de nouvelles modalités de traitement de pathologies.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.
Work with Univserity de Sherbrooke - Centre of Excellence in Pharmacology and Structural Biology on Scientist.com
For prices, more details, or to contact Univserity de Sherbrooke - Centre of Excellence in Pharmacology and Structural Biology, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.